JAMES WALTER BLASETTO

NEWARK, DE

General Payments — all program years on this page

$260,792.50

  • Category: General Payments
  • Program years: PY2020–2024
  • Record count: 41
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $171,815.03 across 17 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $171,180.4510
Travel and Lodging $562.654
Food and Beverage $34.951
Charitable Contribution $18.991
Gift $17.991

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Acerta Pharma LLC $171,815.0317

By program year

Program yearAmountRecords
2020 $12,736.355
2021 $1,163.001
2022 $4,861.794
2023 $70,216.3314
2024 $171,815.0317

Records — PY2024 (17)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1104337134 AstraZeneca Pharmaceuticals LP $252.33 03/25/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1104369915 AstraZeneca Pharmaceuticals LP $17.99 11/27/2024 Gift Undisputed 01/23/2026 View at CMS
1104376845 AstraZeneca Pharmaceuticals LP $33,949.65 10/25/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1104422513 AstraZeneca Pharmaceuticals LP $14.40 04/02/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1104521520 AstraZeneca Pharmaceuticals LP $17,995.50 12/13/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1104640325 AstraZeneca Pharmaceuticals LP $291.33 03/25/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1104695800 AstraZeneca Pharmaceuticals LP $4.59 04/02/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1105221112 AstraZeneca Pharmaceuticals LP $18.99 02/04/2024 Charitable Contribution Undisputed 01/23/2026 View at CMS
1105256403 AstraZeneca Pharmaceuticals LP $5,245.20 02/01/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1105268306 AstraZeneca Pharmaceuticals LP $10,220.70 08/15/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1105419865 AstraZeneca Pharmaceuticals LP $34.95 12/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105435921 AstraZeneca Pharmaceuticals LP $48,094.95 08/08/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1105484959 AstraZeneca Pharmaceuticals LP $13,350.15 12/06/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1105691357 AstraZeneca Pharmaceuticals LP $14,391.75 09/03/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1105698962 AstraZeneca Pharmaceuticals LP $5,189.40 01/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1105777488 AstraZeneca Pharmaceuticals LP $9,653.40 11/15/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1105796682 AstraZeneca Pharmaceuticals LP $13,089.75 09/02/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.